patented technology to grow and expand adult Stem Cells
Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place
Message: for those who don't read yahoo message board
Pluristem is preparing to deal with pharmaceutical giant after the successful clinical trial!
Just released news: Zami Aberman Pluristem CEO, in personal interview after the conference yesterday with the Financial newspaper: "The Marker".
Later I'll send some important quotes.
-
Great News !
Sentiment: Strong Buy
-
Zami Aberman is Giving Multiple Talks Next Tuesday & Wednesday in Washington D.C. I bet he will be in discussions with those companies after he finishes his business at the 10th annual Phacilitate Cell & Gene Therapy Forum.
Presenter: Zami Aberman, Chairman & CEO
1. Jan 28th, 2014, 10:15AM ET - Panel Discussion - How are phase I/II C> companies "blocking and tackling" to prepare for commercialization? What are the key questions to ask your development and commercial teams before you reach phase III?
2. Jan 28th, 2014, 05:20PM ET - Panel Discussion - What are the key issues for consideration to assess the viability of such a business model?
3. Jan 29th, 2014, 10:55AM ET - 3D culturing of MSC opens new possibilities for screening, toxicology and diagnostics.
4. Jan 29th, 2014, 12:45PM ET - Focus Session 3 - Case study - The challenges in the design and implementation of a multi-national, FDA/EMA approved PAD clinical study. LessSentiment: Strong Buy
- 2 Replies to allo_geneic
-
Big Pharma Will Be Fighting To Talk To Zami !
Sentiment: Strong Buy
-
The Pieces of the Puzzle are Beginning To Come Together !
Sentiment: Strong Buy
-
Aberman said that the importance of the current experiment is that the first time Pluristem supports the claims of the effectiveness of its technology and clinical data. "We did not just do this experiment, which began a year and a half ago," said Aberman in an interview with TheMarke.
"pharmaceutical companies have expressed interest in the product, but want to see clinical data, and we have already shown that there is a correlation between the experimental results and the deal"
. He said the company strives to make a commercialization deal based on the clinical data
Three of the four leading pharmaceutical companies in hip surgery implants have expressed interest in the product.
According to estimates, four leading companies are Zimmer, Smith & Nephew, Stryker and Medtronic Less- 3 Replies to biommm
-
He said the company strives to make a commercialization deal based on the clinical data: But doesn't Lonza have interest in this...
Sentiment: Strong Buy
-
Licensing Deal Coming ! Possible Bidding War ?
Sentiment: Strong Buy
-
I would love to know how 'substantive' the expressed interest by these big four companies is in Pluristem's latest clinical trial results. Are we just throwing comments around 'off the cuff' or are these interests that can be backed up by some other evidential means?
Sentiment: Buy
-
CEO Zami Aberman: "Three of the four leading companies in the field showed interest in the product. They just waited for the clinical data "
- 2 Replies to biommm
-
Thanks. Appreciate thoughtful info-based posts.
-
Excellent Reporting Again Biommm ! Keep Up The Good Work !
Sentiment: Strong Buy
2 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply